X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

EVLO

Closed

Evelo Biosciences Inc

0.0005
0.0000 (0.00%)
Last Update: 01 Jul 2025 16:30:00
Yesterday: 0.0005
Day's Range: 0.0005 - 0.0005
Send
When Written:
 
0.1807
Evelo Biosciences Inc is a clinical-stage biotechnology company that is focused on developing monoclonal microbial therapeutics for the treatment of a range of diseases. The company's proprietary platform technology, known as the Microbiome Platform, is designed to harness the power of the human microbiome to develop therapies that target specific diseases.

Evelo Biosciences is headquartered in Cambridge, Massachusetts, and was founded in 2014 by Noubar Afeyan, Flagship Pioneering, and David Berry. The company went public in 2018 and is listed on the NASDAQ under the ticker symbol "EVLO."

The company's lead product candidate, EDP1815, is being developed for the treatment of psoriasis and other inflammatory diseases. Evelo Biosciences is also developing other product candidates targeting various diseases, including cancer, autoimmune disorders, and metabolic diseases.

Evelo Biosciences has partnerships with several leading pharmaceutical companies, including Merck, Sanofi, and Mayo Clinic. The company has received funding from several venture capital firms, including Flagship Pioneering, Polaris Partners, and GV.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.153
X